Glioblastoma Multiforme
Conditions
Keywords
Chemoresistance, Autophagy, Ferropotosis, DRD2, Haloperidol
Brief summary
The study of investigators indicated that TMZ can up-regulate dopamine D2 receptor (DRD2) expression, and mediates Ferroptosis inhibition and chemoresistance of GBM. The clinical data also proved that the DRD2 expression in recurrent GBM is significantly higher than that in primary GBM. Moreover, the DRD2 antagonist haloperidol can attenuate the above function of DRD2, and increase the sensitivity of GBM to the TMZ by inducing fatal autophagy and ferroptosis. In xenograft mice, the combined usage of haloperidol and Temozolomide (TMZ) can significantly inhibit tumor growth and increase overall survival. The investigators' findings have been published in Clinical cancer research. Haloperidol known as a butylbenzene antipsychotic drug, has been widely used in several kinds of mental illnesses, such as depression, schizophrenia, and Bipolar disorder. And the safe dosage of the haloperidol is clear so far. So in this study, the investigators will recruit the patients who suffered from recurrent GBM, and evaluate the effectiveness of single TMZ chemotherapy or combined with haloperidol.
Interventions
DRUGHaloperidol Tablets
Haloperidol tablet 6mg, Oral, Triple/Day
DRUGTemozolomide
Temozolomide, 150mg/kg, Oral, Once/Day, 5/28 days
Sponsors
Southern Medical University, China
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Adult patients * Primary GBM underwent surgery and TMZ chemoradiotherapy, and MRI confirmed the tumor recurrence * Without severe cardiac diseases
Exclusion criteria
* Child patients (\<18 years) * Recurrence tumors grow fast, which needs surgery removal * H3K27M midline glioblastoma * Suffered with severe cardiac diseases
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of partial relief and complete relief | 3 months | Detected the percentage of partial relief and complete relief according to RANO criteria. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | One year | Overall survival was evaluated during follow-up period. |
| DRD2 expression | One year | If the recurrent GBM underwent surgery resection, the DRD2 expression was detected. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Adverse drug reaction of haloperidol | One year | Detection the adverse drug reaction of haloperidol |
Contacts
Primary ContactYuntao Lu, Ph.D
Outcome results
None listed